14 Sep

Sarepta Therapeutics Has Returned 169.97% Year-to-Date

WRITTEN BY Margaret Patrick

Revenue and earnings trends

Sarepta Therapeutics (SRPT) has returned 169.97% YTD (year-to-date). In the second quarter, it reported EPS of -$0.43, surpassing the consensus estimate by $0.46. EXONDYS 51 sales were $73.5 million in the quarter, which is a YoY (year-over-year) rise of 110%. EXONDYS sales were $138 million in the first half of 2018. The company expects to report $295 million–$305 million in sales of EXONDYS 51 in 2018.

Sarepta Therapeutics Has Returned 169.97% Year-to-Date

Analyst recommendations for Sarepta Therapeutics

The consensus recommendation for Sarepta Therapeutics over the next 12 months is a “buy.” Of the 21 analysts covering the stock in September, seven have recommended a “strong buy,” 13 have recommended a “buy,” and one has recommended a “hold.”

Wall Street analysts have projected a 12-month consensus target price of $188.58, which is a 25.54% rise over its closing price on September 13.

Growth drivers

By the end of 2018, Sarepta Therapeutics plans to submit a rolling NDA (New Drug Application) to the FDA for golodirsen, an investigational phosphorodiamidate Morpholino oligomer (or PMO) therapy, in Duchenne muscular dystrophy (or DMD) due to deletions in the DMD gene related to exon 53 skipping. The company has estimated that 8% of DMD patients have exon 53 amenable mutations in their DMD gene. The company expects an FDA decision in 2019.

Sarepta Therapeutics is studying another investigational PMO therapy, casimersen, in the Phase 3 ESSENCE trial for DMD patients with DMD gene mutations amenable to exon 45 skipping. The company has conducted a Type C meeting with the FDA related to this trial. These efforts may accelerate the FDA approval process for casimersen.

While 13% of the DMD patient population is currently eligible for treatment with EXONDYS 51, regulatory approvals for casimersen and golodirsen are expected to expand the addressable market opportunity for Sarepta Therapeutics to 30% of the DMD patient population.

Next, let’s look at the growth trends for Regenxbio.

Latest articles

15 Jul

Will Amazon Prime Day 2019 Break 2018's Record?

WRITTEN BY Jitendra Parashar

This year, Amazon extended its Prime Day to 48 hours instead of the 36-hour sale in July 2018, making the 2019 event the longest Prime Day ever.

In a series of tweets on Monday, Trump today weighed in on China’s GDP growth, which came in at a 27-year low.

15 Jul

OrganiGram's Third-Quarter Earnings

WRITTEN BY Adam Jones

On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

Trump is reportedly planning to increase the content of US-made steel in federal projects, which would be a lifeline for US steel companies.

Huawei is preparing for “extensive layoffs” in the US, which could put the US-China trade deal on the rocks.

With Q2's Netflix earnings just around the corner, here's what you can expect from the online streaming giant and the broader streaming space.